Length of psychiatric hospitalization and prediction of antipsychotic response

Frank P. Zemian, Ole J Thienhaus, David L. Garver

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

1. 1. Clinical variables determining length of psychiatric hospitalization for psychotic inpatients were explored. Forty psychotic inpatients received a 14 day fixed dose neuroleptic trial. 2. 2. Neuroleptic responders ( 25 40) were discharged 15 ± 2 days after initiation of phannacotherapy. For neuroleptic non-responders ( 15 40) antipsychotic medication was then altered as clinically indicated. Patients requiring one change in medication (N = 8) were discharged after 27 ± 5 days; those requiring two medication adjustments (N = 4) were discharged after 33 ± 3 days and those requiring three alterations in phannacotherapy (N = 3) were discharged after 42 ± 12 days. 3. 3. Statistical analysis of clinical and diagnostic variables indicated that 84% of the variation in length of hospitalization was accounted for by the number of alterations in phannacotherapy required for symptom remission and discharge. It is suggested that length of hospitalization may be decreased by decreasing the length of time a clinician prescribes phannacotherapy that subsequently proves not effective. 4. 4. Bayesian analysis was employed to identify the minimum length of pharmacotherapy which accurately predicts subsequent antipsychotic response/non-response. During the fixed dose neuroleptic trial response/non-response could be accurately predicted for 65% of the patients by Day 3 of the trial while by Day 7 response/non-response could be predicted for 80% of the patients. 5. 5. The present data indicate that a three to seven day trial of antipsychotics may be sufficient for making phannacotherapy decisions as such a trial demonstrates a diagnostic efficiency similar to other predictive tests employed in clinical medicine.

Original languageEnglish (US)
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume14
Issue number1
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Antipsychotic Agents
Psychiatry
Hospitalization
Inpatients
Social Adjustment
Bayes Theorem
Clinical Medicine
Decision Making
Drug Therapy

Keywords

  • 5-HT
  • Length of stay
  • neuroleptic
  • New Haven Schizophrenic Index
  • NHSI
  • psychosis
  • schizophrenia
  • serotonin receptor
  • subtype 3
  • symptom remission

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Length of psychiatric hospitalization and prediction of antipsychotic response. / Zemian, Frank P.; Thienhaus, Ole J; Garver, David L.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 14, No. 1, 1990.

Research output: Contribution to journalArticle

@article{0eea492b2e424a8fb08c9b3369f810cb,
title = "Length of psychiatric hospitalization and prediction of antipsychotic response",
abstract = "1. 1. Clinical variables determining length of psychiatric hospitalization for psychotic inpatients were explored. Forty psychotic inpatients received a 14 day fixed dose neuroleptic trial. 2. 2. Neuroleptic responders ( 25 40) were discharged 15 ± 2 days after initiation of phannacotherapy. For neuroleptic non-responders ( 15 40) antipsychotic medication was then altered as clinically indicated. Patients requiring one change in medication (N = 8) were discharged after 27 ± 5 days; those requiring two medication adjustments (N = 4) were discharged after 33 ± 3 days and those requiring three alterations in phannacotherapy (N = 3) were discharged after 42 ± 12 days. 3. 3. Statistical analysis of clinical and diagnostic variables indicated that 84{\%} of the variation in length of hospitalization was accounted for by the number of alterations in phannacotherapy required for symptom remission and discharge. It is suggested that length of hospitalization may be decreased by decreasing the length of time a clinician prescribes phannacotherapy that subsequently proves not effective. 4. 4. Bayesian analysis was employed to identify the minimum length of pharmacotherapy which accurately predicts subsequent antipsychotic response/non-response. During the fixed dose neuroleptic trial response/non-response could be accurately predicted for 65{\%} of the patients by Day 3 of the trial while by Day 7 response/non-response could be predicted for 80{\%} of the patients. 5. 5. The present data indicate that a three to seven day trial of antipsychotics may be sufficient for making phannacotherapy decisions as such a trial demonstrates a diagnostic efficiency similar to other predictive tests employed in clinical medicine.",
keywords = "5-HT, Length of stay, neuroleptic, New Haven Schizophrenic Index, NHSI, psychosis, schizophrenia, serotonin receptor, subtype 3, symptom remission",
author = "Zemian, {Frank P.} and Thienhaus, {Ole J} and Garver, {David L.}",
year = "1990",
doi = "10.1016/0278-5846(90)90060-T",
language = "English (US)",
volume = "14",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Length of psychiatric hospitalization and prediction of antipsychotic response

AU - Zemian, Frank P.

AU - Thienhaus, Ole J

AU - Garver, David L.

PY - 1990

Y1 - 1990

N2 - 1. 1. Clinical variables determining length of psychiatric hospitalization for psychotic inpatients were explored. Forty psychotic inpatients received a 14 day fixed dose neuroleptic trial. 2. 2. Neuroleptic responders ( 25 40) were discharged 15 ± 2 days after initiation of phannacotherapy. For neuroleptic non-responders ( 15 40) antipsychotic medication was then altered as clinically indicated. Patients requiring one change in medication (N = 8) were discharged after 27 ± 5 days; those requiring two medication adjustments (N = 4) were discharged after 33 ± 3 days and those requiring three alterations in phannacotherapy (N = 3) were discharged after 42 ± 12 days. 3. 3. Statistical analysis of clinical and diagnostic variables indicated that 84% of the variation in length of hospitalization was accounted for by the number of alterations in phannacotherapy required for symptom remission and discharge. It is suggested that length of hospitalization may be decreased by decreasing the length of time a clinician prescribes phannacotherapy that subsequently proves not effective. 4. 4. Bayesian analysis was employed to identify the minimum length of pharmacotherapy which accurately predicts subsequent antipsychotic response/non-response. During the fixed dose neuroleptic trial response/non-response could be accurately predicted for 65% of the patients by Day 3 of the trial while by Day 7 response/non-response could be predicted for 80% of the patients. 5. 5. The present data indicate that a three to seven day trial of antipsychotics may be sufficient for making phannacotherapy decisions as such a trial demonstrates a diagnostic efficiency similar to other predictive tests employed in clinical medicine.

AB - 1. 1. Clinical variables determining length of psychiatric hospitalization for psychotic inpatients were explored. Forty psychotic inpatients received a 14 day fixed dose neuroleptic trial. 2. 2. Neuroleptic responders ( 25 40) were discharged 15 ± 2 days after initiation of phannacotherapy. For neuroleptic non-responders ( 15 40) antipsychotic medication was then altered as clinically indicated. Patients requiring one change in medication (N = 8) were discharged after 27 ± 5 days; those requiring two medication adjustments (N = 4) were discharged after 33 ± 3 days and those requiring three alterations in phannacotherapy (N = 3) were discharged after 42 ± 12 days. 3. 3. Statistical analysis of clinical and diagnostic variables indicated that 84% of the variation in length of hospitalization was accounted for by the number of alterations in phannacotherapy required for symptom remission and discharge. It is suggested that length of hospitalization may be decreased by decreasing the length of time a clinician prescribes phannacotherapy that subsequently proves not effective. 4. 4. Bayesian analysis was employed to identify the minimum length of pharmacotherapy which accurately predicts subsequent antipsychotic response/non-response. During the fixed dose neuroleptic trial response/non-response could be accurately predicted for 65% of the patients by Day 3 of the trial while by Day 7 response/non-response could be predicted for 80% of the patients. 5. 5. The present data indicate that a three to seven day trial of antipsychotics may be sufficient for making phannacotherapy decisions as such a trial demonstrates a diagnostic efficiency similar to other predictive tests employed in clinical medicine.

KW - 5-HT

KW - Length of stay

KW - neuroleptic

KW - New Haven Schizophrenic Index

KW - NHSI

KW - psychosis

KW - schizophrenia

KW - serotonin receptor

KW - subtype 3

KW - symptom remission

UR - http://www.scopus.com/inward/record.url?scp=29944442648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29944442648&partnerID=8YFLogxK

U2 - 10.1016/0278-5846(90)90060-T

DO - 10.1016/0278-5846(90)90060-T

M3 - Article

VL - 14

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -